Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma is organized by i3 Health and will be held from Mar 01, 2023 - Feb 29, 2024.

Module 01:
Statement of Need:
Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Module 1 of this continuing pharmacy education (CPE)–approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.

Learning Objectives:
Upon completion of this activity, participants should be able to

Assess guideline-recommended treatment combination and sequencing strategies for NDMM
Review the mechanism of action, efficacy, and safety of anti-CD38 monoclonal antibodies in the treatment of NDMM

Module 02:
Statement of Need:
New technologies are leading to deeper responses and longer survival for patients with multiple myeloma, but these complex care plans lead to questions about how to optimize care. Clinicians are challenged with leveraging the best available evidence and meeting individual care needs in diverse patient populations across different settings. Gaps remain in promoting collaboration between the multidisciplinary team and managed care professionals in their goal of providing value-based treatment and survivorship care plans. In Module 2 of this continuing pharmacy education (CPE)–approved activity, Eric Cannon, PharmD, FAMCP, Chief Pharmacy Benefits Officer at SelectHealth, will explore strategies for aligning treatment goals and value-based care for patients with newly diagnosed multiple myeloma.

Learning Objectives:
Upon completion of this activity, participants should be able to

Discuss strategies for developing evidence- and value-based care plans for patients with NDMM

Faculty:
Joseph A. Kalis, PharmD, BCOP (Co-Chair)
Ambulatory Oncology Clinical Pharmacy Specialist
University of Colorado Health

Eric Cannon, PharmD, FAMCP (Co-Chair)
Chief Pharmacy Benefits Officer
SelectHealth
General Manager, Scripius

This 2-module continuing pharmacy education—(CPE) Strategy Session brings together 2 expert pharmacists to discuss treatment goals and value-based care for patients with newly diagnosed multiple myeloma. Learners must complete both modules to receive credit.

In Module 1 of this CPE-approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.

In Module 2 of this CPE-approved activity, Eric Cannon, PharmD, FAMCP, Chief Pharmacy Benefits Officer at SelectHealth, will explore strategies for aligning treatment goals and value-based care for patients with newly diagnosed multiple myeloma.

Start the activity now!